DGAT2L6

Summary

DGAT2L6 (diacylglycerol O-acyltransferase 2 like 6, HGNC:23250) is a protein-coding gene on chromosome Xq13.1, encoding Diacylglycerol O-acyltransferase 2-like protein 6 (Q6ZPD8). Diglyceride acyltransferase that uses fatty acyl-CoA as substrate.

This gene is a member of the diacylglycerol acyltransferase 2 family. The encoded protein is a putative acyltransferase and is most likely involved in the synthesis of di- or triacylglycerol, however its substrate specificity is currently unknown.

Source: NCBI Gene 347516 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 76 total
• Druggable target: yes
• MANE Select transcript: NM_198512

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23250
Approved symbol	DGAT2L6
Name	diacylglycerol O-acyltransferase 2 like 6
Location	Xq13.1
Locus type	gene with protein product
Status	Approved
Aliases	DC3, FLJ25989
Ensembl gene	ENSG00000184210
Ensembl biotype	protein_coding
OMIM	300926
Entrez	347516

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000333026

RefSeq mRNA: 1 — MANE Select: NM_198512 NM_198512

CCDS: CCDS14397

Canonical transcript exons

ENST00000333026 — 7 exons

Exon	Start	End
ENSE00001302430	70200255	70200459
ENSE00001307744	70199812	70199882
ENSE00001322588	70201890	70202064
ENSE00001329802	70199271	70199381
ENSE00001364288	70177483	70177667
ENSE00001371388	70204305	70204516
ENSE00001375946	70204952	70205704

Expression profiles

Bgee: expression breadth tissue_specific, 9 present calls, max score 54.99.

Top tissues by expression

122 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	54.99	silver quality
skin of abdomen	UBERON:0001416	53.45	gold quality
zone of skin	UBERON:0000014	49.91	gold quality
skin of leg	UBERON:0001511	47.11	gold quality
bone marrow cell	CL:0002092	44.43	gold quality
colonic epithelium	UBERON:0000397	41.46	gold quality
bone marrow	UBERON:0002371	40.89	gold quality
skeletal muscle tissue	UBERON:0001134	38.18	gold quality
right lung	UBERON:0002167	37.66	silver quality
right uterine tube	UBERON:0001302	37.02	silver quality
tonsil	UBERON:0002372	36.86	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
granulocyte	CL:0000094	35.48	gold quality
muscle tissue	UBERON:0002385	34.58	gold quality
descending thoracic aorta	UBERON:0002345	34.47	gold quality
mucosa of stomach	UBERON:0001199	34.08	gold quality
muscle of leg	UBERON:0001383	33.82	gold quality
corpus callosum	UBERON:0002336	33.45	gold quality
gastrocnemius	UBERON:0001388	32.78	gold quality
duodenum	UBERON:0002114	32.73	gold quality
left uterine tube	UBERON:0001303	32.46	gold quality
liver	UBERON:0002107	32.40	gold quality
uterine cervix	UBERON:0000002	32.32	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
placenta	UBERON:0001987	31.45	gold quality
rectum	UBERON:0001052	31.33	gold quality
endometrium	UBERON:0001295	31.11	gold quality
adrenal tissue	UBERON:0018303	31.06	gold quality
subcutaneous adipose tissue	UBERON:0002190	30.98	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.95

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

21 targeting DGAT2L6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-29A-5P	99.08	68.59	1813
HSA-MIR-299-5P	98.56	71.14	1140
HSA-MIR-4691-3P	98.11	66.83	1204
HSA-MIR-6870-3P	98.08	65.10	692
HSA-MIR-6842-3P	98.07	66.33	1325
HSA-MIR-18B-3P	98.05	65.55	595
HSA-MIR-744-3P	97.99	67.76	637
HSA-MIR-3652	97.71	65.43	1890
HSA-MIR-192-3P	97.52	67.66	1001
HSA-MIR-4430	97.47	65.61	1813
HSA-MIR-6822-3P	96.60	66.06	680
HSA-MIR-4680-5P	96.43	67.15	893
HSA-MIR-9900	96.06	65.48	557
HSA-MIR-3157-3P	95.86	67.08	454
HSA-MIR-6816-3P	95.05	66.08	459

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
mus_musculus	Dgat2l6	ENSMUSG00000067597
rattus_norvegicus	Dgat2l6	ENSRNOG00000038046
drosophila_melanogaster	CG1941	FBGN0033214
drosophila_melanogaster	Dgat2	FBGN0033215
drosophila_melanogaster	CG1946	FBGN0033216
caenorhabditis_elegans		WBGENE00010296
caenorhabditis_elegans		WBGENE00019464
caenorhabditis_elegans		WBGENE00020910
caenorhabditis_elegans		WBGENE00021818

Paralogs (6): DGAT2 (ENSG00000062282), MOGAT3 (ENSG00000106384), MOGAT1 (ENSG00000124003), AWAT2 (ENSG00000147160), MOGAT2 (ENSG00000166391), AWAT1 (ENSG00000204195)

Protein

Protein identifiers

Diacylglycerol O-acyltransferase 2-like protein 6 — Q6ZPD8 (reviewed: Q6ZPD8)

Alternative names: Diacylglycerol O-acyltransferase candidate 3

All UniProt accessions (1): Q6ZPD8

UniProt curated annotations — full annotation on UniProt →

Function. Diglyceride acyltransferase that uses fatty acyl-CoA as substrate. Particularly active with oleate as a substrate. Has no wax synthase activity to produce wax esters. Able to use 1-monoalkylglycerol (1-MAkG) as an acyl acceptor for the synthesis of monoalkyl-monoacylglycerol (MAMAG).

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Expressed in all tissues tested except pancreas.

Similarity. Belongs to the diacylglycerol acyltransferase family.

RefSeq proteins (1): NP_940914* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007130	DAGAT	Family

Pfam: PF03982

Enzyme classification (BRENDA):

• EC 2.3.1.20 — diacylglycerol O-acyltransferase (BRENDA: 78 organisms, 288 substrates, 261 inhibitors, 50 Km, 1 kcat entries)
• EC 2.3.1.75 — long-chain-alcohol O-fatty-acyltransferase (BRENDA: 24 organisms, 473 substrates, 10 inhibitors, 48 Km, 37 kcat entries)

Substrate kinetics (BRENDA)

29 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
OLEOYL-COA	0.0005–0.667	20
PALMITOYL-COA	0.0007–0.39	6
PALMITOYL-COA	0.0031–0.029	6
ARACHIDONOYL-COA	0.2263–0.2972	4
DECANOYL-COA	0.001–0.0176	4
EICOSAPENTAENOYL-COA	0.1016–0.1312	4
LAUROYL-COA	0.0001–0.0259	4
MYRISTOYL-COA	0.0039–0.0185	4
OCTADECATRIENOYL-COA	0.2809–0.2847	4
OCTANOYL-COA	0.0123–0.0299	4
STEAROYL-COA	0.0192–0.0759	4
DIOLEIN	0.028–0.714	2
SN-1,2-DIOLEIN	0.006–0.113	2
1,2-DIOLEIN	0.014	1
1,2-DIOLEOYL-SN-GLYCEROL	0.5971	1

Catalyzed reactions (Rhea), 3 shown:

• 1-(9Z-octadecenoyl)-glycerol + (9Z)-octadecenoyl-CoA = 1,2-di-(9Z-octadecenoyl)-glycerol + CoA (RHEA:37915)
• 1,2-di-(9Z-octadecenoyl)-sn-glycerol + (9Z)-octadecenoyl-CoA = 1,2,3-tri-(9Z-octadecenoyl)-glycerol + CoA (RHEA:38219)
• 1-O-(9Z-octadecenyl)-glycerol + (9Z)-octadecenoyl-CoA = 1-O-(9Z-octadecyl)-3-(9Z-octadecenoyl)-glycerol + CoA (RHEA:55340)

UniProt features (3 total): transmembrane region 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZPD8-F1	92.02	0.77

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1482883	Acyl chain remodeling of DAG and TAG

MSigDB gene sets: 29 (showing top): GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GOBP_GLYCEROLIPID_BIOSYNTHETIC_PROCESS, GOBP_NEUTRAL_LIPID_BIOSYNTHETIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_NEUTRAL_LIPID_METABOLIC_PROCESS, GOBP_LIPID_BIOSYNTHETIC_PROCESS, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOCC_ORGANELLE_SUBCOMPARTMENT, GOMF_ACYLGLYCEROL_O_ACYLTRANSFERASE_ACTIVITY, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_O_ACYLTRANSFERASE_ACTIVITY, chrXq13, REACTOME_ACYL_CHAIN_REMODELING_OF_DAG_AND_TAG, REACTOME_METABOLISM_OF_LIPIDS, GOBP_MONOACYLGLYCEROL_METABOLIC_PROCESS

GO Biological Process (3): lipid metabolic process (GO:0006629), monoacylglycerol biosynthetic process (GO:0006640), acylglycerol acyl-chain remodeling (GO:0036155)

GO Molecular Function (5): diacylglycerol O-acyltransferase activity (GO:0004144), obsolete O-acyltransferase activity (GO:0008374), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (3): endoplasmic reticulum membrane (GO:0005789), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
primary metabolic process	1
monoacylglycerol metabolic process	1
acylglycerol biosynthetic process	1
acylglycerol metabolic process	1
acylglycerol O-acyltransferase activity	1
binding	1
catalytic activity	1
transferase activity	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

540 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DGAT2L6	KRTAP17-1	Q9BYP8	421
DGAT2L6	TMEM68	Q96MH6	389
DGAT2L6	FAR2	Q96K12	377
DGAT2L6	SLC22A14	Q9Y267	369
DGAT2L6	PRSS53	Q2L4Q9	357
DGAT2L6	AASDH	Q4L235	349
DGAT2L6	LPCAT4	Q643R3	345
DGAT2L6	SORCS3	Q9UPU3	327
DGAT2L6	SLC15A5	A6NIM6	325
DGAT2L6	DNASE1L2	Q92874	322
DGAT2L6	GDPD2	Q9HCC8	321
DGAT2L6	MPLKIP	Q8TAP9	319
DGAT2L6	ELOVL3	Q9HB03	319
DGAT2L6	FABP9	Q0Z7S8	316
DGAT2L6	OTUD6A	Q7L8S5	313

IntAct

137 interactions, top by confidence:

A	B	Type	Score
DGAT2L6	SCN3B	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	TMEM143	psi-mi:“MI:0915”(physical association)	0.560
TUFM	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
FARS2	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
GAD2	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
FBXL19	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
MPP1	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	PITPNC1	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	NDRG4	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	MYG1	psi-mi:“MI:0915”(physical association)	0.560
SNX4	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	SMG9	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	RNF5	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	WIPI2	psi-mi:“MI:0915”(physical association)	0.560
TTPA	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	NAPB	psi-mi:“MI:0915”(physical association)	0.560
STAR	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	MCEMP1	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	TMEM255B	psi-mi:“MI:0915”(physical association)	0.560
ECPAS	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	PBX3	psi-mi:“MI:0915”(physical association)	0.560
TMED8	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	MTERF4	psi-mi:“MI:0915”(physical association)	0.560
SCAND1	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	ABHD5	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	ACSF2	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	ABHD4	psi-mi:“MI:0915”(physical association)	0.560
DGAT2L6	THAP4	psi-mi:“MI:0915”(physical association)	0.560
ARFIP2	DGAT2L6	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (46): DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid), DGAT2L6 (Two-hybrid)

ESM2 similar proteins: A0A1B0GVX0, A2ADU8, A2ADU9, A2Y075, A6QP72, O82232, P34655, P55017, P55018, P56508, P59158, P68178, P68179, Q0DKW8, Q0VBW2, Q22701, Q3ZCB2, Q53GD3, Q54RZ2, Q5REK4, Q5RJI2, Q5TYP8, Q66I68, Q6DK93, Q6DK99, Q6E1M8, Q6E213, Q6GMG8, Q6GZQ0, Q6NUC1, Q6P828, Q6PCW6, Q6ZPD8, Q8H5T6, Q8NG11, Q8QZY6, Q8S5M8, Q91VA1, Q9ARD5, Q9BYD5

Diamond homologs: A2ADU8, A2ADU9, A6QP72, K7K424, O74850, Q08650, Q28C88, Q2KHS5, Q3KPP4, Q3SYC2, Q4V9F0, Q54GC1, Q58HT5, Q5FVP8, Q5M7F4, Q5M8H5, Q6E1M8, Q6E213, Q6P342, Q6PAZ3, Q6ZPD8, Q70VZ7, Q70VZ8, Q75BY0, Q80W94, Q86VF5, Q91ZV4, Q96PD6, Q96PD7, Q96UY1, Q96UY2, Q9ASU1, Q9DCV3, A1A442, Q9ZVN2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

76 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	12
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1116 predictions. Top by Δscore:

Variant	Effect	Δscore
X:70204950:A:AG	acceptor_gain	1.0000
X:70204950:AGTT:A	acceptor_gain	1.0000
X:70204951:G:GG	acceptor_gain	1.0000
X:70204951:GTT:G	acceptor_gain	1.0000
X:70204951:GTTG:G	acceptor_gain	1.0000
X:70199880:AAG:A	donor_gain	0.9900
X:70201080:A:G	acceptor_gain	0.9900
X:70202026:GCAGC:G	donor_gain	0.9900
X:70202029:GC:G	donor_gain	0.9900
X:70202063:GG:G	donor_gain	0.9900
X:70202064:GG:G	donor_gain	0.9900
X:70204949:T:G	acceptor_gain	0.9900
X:70204950:AGTTG:A	acceptor_gain	0.9900
X:70204951:GTTGG:G	acceptor_gain	0.9900
X:70177664:TTAGG:T	donor_loss	0.9800
X:70177665:TAGG:T	donor_loss	0.9800
X:70177666:AGGT:A	donor_loss	0.9800
X:70177668:G:GA	donor_loss	0.9800
X:70177669:T:A	donor_loss	0.9800
X:70201074:T:TA	acceptor_gain	0.9800
X:70201083:A:AG	acceptor_gain	0.9800
X:70201084:G:GG	acceptor_gain	0.9800
X:70202034:AAG:A	donor_gain	0.9800
X:70204948:ATAG:A	acceptor_loss	0.9800
X:70204951:GT:G	acceptor_gain	0.9800
X:70204948:A:AG	acceptor_gain	0.9700
X:70177613:G:GT	donor_gain	0.9600
X:70177670:GAGT:G	donor_loss	0.9600
X:70199313:GTAA:G	acceptor_gain	0.9600
X:70200329:T:TA	acceptor_gain	0.9600

AlphaMissense

2187 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:70204330:T:C	F225L	0.968
X:70204332:T:A	F225L	0.968
X:70204332:T:G	F225L	0.968
X:70202039:T:C	F208L	0.966
X:70202041:T:A	F208L	0.966
X:70202041:T:G	F208L	0.966
X:70205047:T:C	F319L	0.960
X:70205049:T:A	F319L	0.960
X:70205049:T:G	F319L	0.960
X:70204316:T:A	V220D	0.951
X:70199871:T:C	F86L	0.931
X:70199873:C:A	F86L	0.931
X:70199873:C:G	F86L	0.931
X:70200420:T:C	F145L	0.925
X:70200422:T:A	F145L	0.925
X:70200422:T:G	F145L	0.925
X:70205061:A:C	K323N	0.922
X:70205061:A:T	K323N	0.922
X:70204514:T:A	V286D	0.921
X:70200345:T:C	F120L	0.918
X:70200347:T:A	F120L	0.918
X:70200347:T:G	F120L	0.918
X:70200439:G:C	R151P	0.913
X:70202040:T:C	F208S	0.910
X:70202052:C:A	A212E	0.910
X:70204324:T:G	Y223D	0.908
X:70204313:T:A	L219H	0.906
X:70200344:C:A	N119K	0.897
X:70200344:C:G	N119K	0.897
X:70204952:T:A	V287D	0.896

dbSNP variants (sampled 300 via entrez): RS1000049877 (X:70205991 T>C), RS1000498447 (X:70181726 T>C), RS1000627444 (X:70191797 A>G), RS1000948757 (X:70201214 C>T), RS1000979029 (X:70184224 G>A), RS1000997861 (X:70196645 TAA>T), RS1001101799 (X:70197961 G>C), RS1001269349 (X:70190501 G>A), RS1001323934 (X:70181063 C>G), RS1001387759 (X:70200938 A>G,T), RS1001416725 (X:70180451 CA>C,CAA), RS1001849196 (X:70200202 G>A,C,T), RS1002003682 (X:70182936 G>T), RS1002070675 (X:70193262 C>T), RS1002268454 (X:70192918 A>G)

Disease associations

OMIM: gene MIM:300926 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465322 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Resveratrol	decreases expression, affects cotreatment	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Valproic Acid	decreases methylation	1
Cadmium Chloride	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5368894	Binding	Inhibition of recombinant human DC3	Discovery of 12 (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders. — J Med Chem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer